%0 Journal Article %A A Semertzidou %A I Kalliala %A H Grout-Smith %A M Kyrgiou %T P86 Diabetes and gynaecological cancers: an umbrella review %D 2019 %R 10.1136/ijgc-2019-ESGO.148 %J International Journal of Gynecologic Cancer %P A106-A106 %V 29 %N Suppl 4 %X Introduction/Background Diabetes mellitus (DM) continues to affect a large proportion of the population and its incidence is on the rise. Many complications associated with it, such as gynaecological cancers, are becoming increasingly apparent. Due to conflicting evidence, it is unknown which outcomes diabetic women are most at risk of. Therefore, the aim of this review is to evaluate the strength and validity of the existing evidence between diabetes and the risk of gynaecological cancers.Methodology Design: Umbrella review of systematic reviews and meta-analyses.Eligibility criteria: Systematic reviews and meta analyses of observational studies investigating the relationship between type I/2 diabetes mellitus and endometrial, ovarian and cervical cancers.Data analysis: The evidence from the meta-analyses were graded according to a statistical criteria comprised of the random effects estimate of the meta-analyses and of their largest study, the number of cases, 95% prediction intervals, I2statistic of heterogeneity between studies, excess significance bias, small studies effect and sensitivity analysis using credibility ceilings. From this, meta-analyses were classified as strong, highly suggestive, suggestive or weak evidence.Results 60 meta-analyses from 20 eligible papers were assessed, of which 15 looked at the association between type 1/2 diabetes mellitus and gynaecological cancers. A highly suggestive association was found between type 1/2 DM and endometrial cancer incidence. Suggestive associations were found between type 1/2 DM and all-cause mortality in ovarian cancer and overall and recurrence-free survival in cervical cancer.Conclusion DM appears to be strongly associated with endometrial cancer incidence, whereas a weaker association was demonstrated with ovarian and cervical cancer survival and mortality.Disclosure Nothing to disclose. %U https://ijgc.bmj.com/content/ijgc/29/Suppl_4/A106.2.full.pdf